Skip to main content
      Deucravacitinib (TYK2) in PsA from POETYK trials

      Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20)

      Ste

      Mike Putman EBRheum

      4 months 1 week ago
      Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE
      In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions inc

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions increased significantly in axSpA (0.16 units/yr vs –0.02), with 15% having ≥3 lesions at 2 year vs 1% in non-axSpA. Fat lesions may signal early structural https://t.co/zvgU1Gt0po
      #ACR25 Clinical Preview by Prof Coates for use now:

      GLP-1 agonist & Diet

      Abstr#813 GIP/GLP-1 improved MSK pain

      A

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC
      Observational study from VCRC AAV patinet, >70% had pulm involvement at some point

      As expected, nodules favor GPA (6

      Mike Putman EBRheum

      4 months 1 week ago
      Observational study from VCRC AAV patinet, >70% had pulm involvement at some point As expected, nodules favor GPA (63% vs 12% MPA) & DAH favors MPA (61% vs 31%) More ILD in MPA (11% vs 1%) & more endobronchial in GPA (12% vs 2%) Helpful pearls! @RheumNow #ACR25 Abstr#0721 https://t.co/Iu5MdiTABR
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow!

      GC #steroid burden & Mx

      Abstr#738 Survey of #GCA p

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p
      What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing?

      Turns out anything helps - get

      David Liew drdavidliew

      4 months 1 week ago
      What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing? Turns out anything helps - get out there and don’t let perfect be the enemy of good! Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/VGH2rz3dzb
      Does diet matter in PsA?

      Randomized study comparing advice, DASH low calorie, Mediterranean diet

      Seems that weight los

      David Liew drdavidliew

      4 months 1 week ago
      Does diet matter in PsA? Randomized study comparing advice, DASH low calorie, Mediterranean diet Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc
      This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts

      SSc pts had ⬆️rates of seroconversion

      sheila RHEUMarampa

      4 months 1 week ago
      This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts SSc pts had ⬆️rates of seroconversion mean titers ⬆️ from BL Local rxs ⬇️ in SSc pts Systemic rxns comparable among the 2 grps interesting data. longterm studies still needed #ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG
      Trends in Translational Abstracts content this year by Tomas Mustelin in the
      “Abstracts that Will shape research in t

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      Trends in Translational Abstracts content this year by Tomas Mustelin in the “Abstracts that Will shape research in the near Future” Year in Preview session @RheumNow #ACR25 https://t.co/i5CA8cxHeQ
      Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do ex

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow!

      Early Tx

      Abstr#1677 First-line TNFi for 12-mth vs step-

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow! Early Tx Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9
      New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity wa

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity was linked to sacroiliac radiographic progression over 5 years. Lower zonulin and lipopolysaccharides (LPS) levels also associated with progression. Highlights https://t.co/1uBtR4QA97
      Year in Preview

      SLE: 52% subtherapeutic on weight based HCQ dosing

      Precision prescribing needed, more so for CKD

      @Rh

      Jiha Lee JihaRheum

      4 months 1 week ago
      Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx
      Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just righ

      David Liew drdavidliew

      4 months 1 week ago
      Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels. Yet drug concentrations and TDM are not commonplace in many places - time for change Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc
      ×